VORSCHAU

PRESSETERMINE

AKTUELLES PRESSEFOTO



WETTER
Graz: bedeckt
24°
Innsbruck: Regen
22°
Linz: Regen
22°
Wien: bedeckt
20°
© wetter.net

Stadtname / PLZ

AKTIENKURSE
 
ADHOC
Di, 02.08.2022 07:30
Meldung drucken Artikel weiterleiten
pta20220802006
Business news for the stock market
Pressefach Pressefach

4SC AG: Conference call to be hosted on 9 August 2022 to present the half-year report 2022

Planegg-Martinsried (pta006/02.08.2022/07:30) - Planegg-Martinsried, Germany, 2 August 2022 – 4SC AG (4SC, FSE Prime Standard: VSC) will publish its half-year report 2022 on 9 August 2022. On this day, the Management of 4SC AG will host a conference call at 2 pm CEDT (8 am EDT) to inform about important developments in the reporting period and beyond.

Investors, financial analysts, and journalists interested in participating in the conference call can access via the telephone numbers stated below. Please join the event conference 5-10 minutes prior to the start time. You will be asked to provide the confirmation code.

Date: 9 August 2022
Time: 2 pm CEDT (8 am EDT)
Phone Numbers: +49 (0)32 22109 8334 (Germany)
+44 (0)20 3936 2999 (United Kingdom)
+1 646 664 1960 (USA)
Confirmation Code: 511682

A presentation document supporting the conference call will be available on 9 August 2022, at 4SC's website ( http://www.4sc.com/investors/investor-information/conference-calls-webcasts/ ). After the event, a replay can be accessed from there as well.

- Announcement ends -

Further information

About 4SC

4SC AG ( http://www.4SC.com ) is a clinical-stage biopharmaceutical company developing small-molecule drugs that target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises one drug candidate in clinical development: resminostat ( http://www.4sc.com/product-pipeline/resminostat/ ).

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 39 employees as of 31 March 2022 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A3E5C40).

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact

ir-pr@4sc.com
+49 89 700763-0

(Ende)

Aussender: 4SC AG
Fraunhoferstr. 22
82152 Planegg-Martinsried
Deutschland
Ansprechpartner: Jason Loveridge
Tel.: +49 89 700763-0
E-Mail:
Website: www.4sc.de
ISIN(s): DE000A3E5C40 (share)
Börsen: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
4SC AG
   
Wie fanden Sie diese Meldung?
Weitersagen
likes dislike Share Share |
Social Media
ETARGET

FOCUSTHEMA


SPECIALS


Werbung
middleAdvertising